Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Result: In addition, except for only 1 patient with a mutation at rt181 (A181T) in the ALD group, there was not any primary resistance mutation (i.e., I169T, T184A/C/F/G/I/L/M/S, A194T, S202C/G/I, M204I/V/S, N236T, or M250I/L/V) and secondary resistance mutation (i.e., V173L or L180M) found in treatment-naive patients, while 9 putative resistance mutations and 51 pretreatment mutations were detected in these patients.
Discussion: Currently, the well-known classical NA resistance mutat
Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018.
Introduction: A total of 8 HBV classical mutation sites are conventionally tested for HBV patients in most clinical labs, including M204I/V, L180M, T184A/F/I/L/S, L181T/V, M250I/L/V, M236T, S202G, and V207I.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Also, a recent study using direct sequencing of samples from 131 treatment-naive patients infected with genotype C2 reported an overall rate of 12.98% for primary (rtT184A/C/F and rtM204I/V) or compensatory (rtL80I and rtL180M) mutations.
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V, rtN236T and rtM250I/L/V) and secondary substitutions at 3 codons in RT<
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.
PMID: 26889227
2016
Experimental and therapeutic medicine
Abstract: Clonal analysis further revealed that the rtS202G or rtT184F was in all cases co-localized with rtL180M and rtM204V in any single virus isolate clone.
Abstract: In addition, rtT184F was present in ~20% of the viral population during virological breakthrough, at month 24.
Abstract: The rtL180M, rtT184F and rtM204V were predominant during the combination treatment.
Result: 2B may be summarized as follows:
Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Abstract: The rtT184L/I/A/F (50%), rtS202G (25%) and mixed ETV-resistant mutations (25%) were detected at enrollment.
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
PMID: 25061278
2014
Drug design, development and therapy
Discussion: Moreover, Karatayli et al reported that HBV DNA, in seven of eight patients with ETV resistance mutations (T184F/A/L/I, S202G, and M250V), became undetectable with TDF and LAM after 6 months of treatment.
HBV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT